Pyxis Oncology (PYXS) Price to Sales (2024 - 2025)
Pyxis Oncology's (PYXS) quarterly Price to Sales came in at 6.53 in Q4 2025, down 73.0% quarter-over-quarter from 24.19 in Q2 2025.
Powered by 
Analysis
Pyxis Oncology (PYXS) Price to Sales (2024 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has reported Price to Sales for 2 consecutive years, with 6.53 the latest figure, recorded in Q4 2025.
- On a quarterly basis, Price to Sales changed N/A year-over-year to 6.53 in Q4 2025; TTM through Jun 2026 was 13.78, a 43.04% decrease from a year earlier, with the FY2025 full-year figure at 5.2, down 10.21% from the prior year.
- Price to Sales was 6.53 for Q4 2025 at Pyxis Oncology, down from 24.19 in the prior quarter.
- Over five years, Price to Sales peaked at 24.19 in Q2 2025 and troughed at 6.53 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.74 Bn | 192.75 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.96 Bn | 176.78 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.20 Bn | 123.35 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.05 Bn | 74.05 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn |
| 6 | Moderna | 53.67 Bn | 48.54 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.08 Bn | 29.78 Bn | 992.69 Mn |
| 8 | Biogen | 31.91 Bn | 30.62 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.22 Bn | 29.22 Bn | 1.16 Mn |
| 10 | Pyxis Oncology | 206.05 Mn | 173.06 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 6.53 |
| Jun 30, 2025 | 24.19 |
| Mar 31, 2024 | 15.51 |